Growth Metrics

RxSight (RXST) Long-Term Debt Issuances (2020 - 2021)

RxSight posted quarterly Long-Term Debt Issuances of $10.0 million for Q2 2021, up 100.0% on a QoQ basis from $5.0 million in Q1 2021.

RxSight (RXST) has 2 years of Long-Term Debt Issuances data on file, last reported at $10.0 million in Q2 2021.

  • For the quarter ending Q2 2021, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Sep 2022 stood at $10.0 million (down 75.0% YoY), and the FY2023 full-year result was $20.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q2 2021 stood at $10.0 million, up from $5.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $25.0 million in Q4 2020 and bottomed at $5.0 million in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 RxSight 215.82 Mn -2.06 Mn 23.50 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 10.00 Mn
Jun 30, 2021 10.00 Mn
Mar 31, 2021 5.00 Mn
Mar 31, 2021 5.00 Mn
Dec 31, 2020 25.00 Mn
Dec 31, 2020 25.00 Mn